Most Crohn’s Fistulas Are Still Gone a Year After Cx601 Treatment, Trial Shows

Most Crohn’s Fistulas Are Still Gone a Year After Cx601 Treatment, Trial Shows
TiGenix’s Cx601 was able to resolve a painful Crohn's disease condition known as complex perianal fistulas for a year, according to a Phase 3 trial. Only a quarter of the patients whose condition was resolved within 24 weeks of the treatment had it recur by week 52, researchers said. That compared with 44.1 percent recurrence in a group treated with a placebo. An anal fistula is a small channel that can develop between the end of the bowel and the skin near the anus. It can cause bleeding and discharge when defecating, and can be painful. TiGenix will present the results of the ADMIRE-CD Phase 3 clinical trial (NCT01541579) at the Digestive Disease
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *